BBIO

BridgeBio Pharma (BBIO) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

SEC Filings

BlackRock Now Holds 5.1% Of BridgeBio Pharma, With 9.9 Million Shares

The asset manager's passive ownership disclosure lists 9,892,226 shares and says it is not seeking to influence control.

SEC Filings

BridgeBio's Oral Achondroplasia Drug Gets FDA Priority Review, With A February 4, 2027 Target Date

The FDA accepted BridgeBio's application for oral infigratinib in children, and the company filed the October 6 release in an 8-K on Tuesday.